Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 4Vipoma 1Somatostatinoma 1Neoplastic Cells, Circulating 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Adenoma, Islet Cell 1

Interventions

motesanib diphosphate 1epothilone B 1batifiban 1Temozolomide 1Sorafenib 1Oxaliplatin 1Octreotide 1Leucovorin 1Fluorouracil 1Capecitabine 1Bevacizumab 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrinoma × Sorafenib × NET × Clear all
NCT00131911 2014-11-17

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
93 enrolled 10 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡